FDCP
CRL icon

Foster Dykema Cabot & Partners’s Charles River Laboratories CRL Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$473 – 322
2023
Q4 		$473 Buy
+2
New +$393 ﹤0.01% 283

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Foster Dykema Cabot & Partners's CRL Position: Q1 2024 in Review

Foster Dykema Cabot & Partners sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 2 shares — an estimated $473 sold.

Foster Dykema Cabot & Partners first reported a position in CRL in Q4 2023 and held it in 1 quarter. The position peaked at $473 in Q4 2023. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

  • Foster Dykema Cabot & Partners reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
  • Foster Dykema Cabot & Partners sold 2 Charles River Laboratories shares in Q1 2024, an estimated $473.
  • Foster Dykema Cabot & Partners first reported a position in Charles River Laboratories in Q4 2023 and held it in 1 quarter.
  • Foster Dykema Cabot & Partners's Charles River Laboratories position peaked at $473 in Q4 2023.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Foster Dykema Cabot & Partners's 13F filing for Q1 2024, filed 10 May 2024.